STOCKHOLM - October 24, 2023 - Inify Laboratories, a unique laboratory service
that provides cancer diagnostics within pathology, has had a continuous inflow
of patient samples for diagnosis, which is of paramount importance for the
optimization of both the internal laboratory system and the interaction with
customers.

"We have analyzed prostate biopsies on a daily basis since we opened our first
laboratory in June. The feedback has been very positive, and we are experiencing
an increasing interest in our services among urologists and other stake holders.
The awareness about Inify Laboratories is rapidly increasing among our customer
groups," says CEO Fredrik Palm at Inify Laboratories.

What impresses most is the short response time of no more than five days. Also,
the high-quality diagnostic report is seen as a major improvement with value for
the customers.

"Our pathology reports, developed in-house in close collaboration with
experienced urologists, are graphic and structured, making them easy to
interpret which increases patient safety. The urologist clinics that send
prostate biopsies to Inify Laboratories are highly satisfied with our
diagnostics and response times," says Chief Medical Officer Claes Lindh at Inify
Laboratories.

Waiting times for cancer investigations are long and unpredictable, and the
healthcare system is struggling to cope. Inify Laboratories is well positioned
to help, offering fast, reliable diagnostics of the highest quality for all
patients who need it, regardless of where they live.

"We have gathered all the necessary expertise, built and opened our laboratory,
evaluated our diagnostic performance, and are now ready to offer our diagnostic
services to healthcare systems on a broad scale," says Palm.

For further information, please contact CEO Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com

###

About Inify Laboratories

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist from either Inify Laboratories
or the customer's organization. The report is assisted by our own AI, proven in
clinical studies to have world-leading accuracy. The complete workflow is
supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from
ContextVision, with 40 years of experience within digital imaging for medical
applications. It is listed on Euronext Growth Oslo under the ticker INIFY.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.